Cargando…

A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35

The increased resistance of microorganisms to the different antimicrobials available to today has highlighted the need to find new therapeutic agents, including natural and/or synthetic antimicrobial peptides (AMPs). This study has evaluated the antimicrobial activity of synthetic peptide 35409 (RYR...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreto-Santamaría, Adriana, Curtidor, Hernando, Arévalo-Pinzón, Gabriela, Herrera, Chonny, Suárez, Diana, Pérez, Walter H., Patarroyo, Manuel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167725/
https://www.ncbi.nlm.nih.gov/pubmed/28066341
http://dx.doi.org/10.3389/fmicb.2016.02006
_version_ 1782483203308650496
author Barreto-Santamaría, Adriana
Curtidor, Hernando
Arévalo-Pinzón, Gabriela
Herrera, Chonny
Suárez, Diana
Pérez, Walter H.
Patarroyo, Manuel E.
author_facet Barreto-Santamaría, Adriana
Curtidor, Hernando
Arévalo-Pinzón, Gabriela
Herrera, Chonny
Suárez, Diana
Pérez, Walter H.
Patarroyo, Manuel E.
author_sort Barreto-Santamaría, Adriana
collection PubMed
description The increased resistance of microorganisms to the different antimicrobials available to today has highlighted the need to find new therapeutic agents, including natural and/or synthetic antimicrobial peptides (AMPs). This study has evaluated the antimicrobial activity of synthetic peptide 35409 (RYRRKKKMKKALQYIKLLKE) against Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 15442 and Escherichia coli ML 35 (ATCC 43827). The results have shown that peptide 35409 inhibited the growth of these three bacterial strains, having 16-fold greater activity against E. coli and P. aeruginosa, but requiring less concentration regarding E. coli (22 μM). When analyzing this activity against E. coli compared to time taken, it was found that this peptide inhibited bacterial growth during the first 60 min and reduced CFU/mL 1 log after 120 min had elapsed. This AMP permeabilized the E. coli membrane by interaction with membrane phospholipids, mainly phosphatidylethanolamine, inhibited cell division and induced filamentation, suggesting two different targets of action within a bacterial cell. Cytotoxicity studies revealed that peptide 35409 had low hemolytic activity and was not cytotoxic for two human cell lines. We would thus propose, in the light of these findings, that the peptide 35409 sequence should provide a promising template for designing broad-spectrum AMPs.
format Online
Article
Text
id pubmed-5167725
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-51677252017-01-06 A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35 Barreto-Santamaría, Adriana Curtidor, Hernando Arévalo-Pinzón, Gabriela Herrera, Chonny Suárez, Diana Pérez, Walter H. Patarroyo, Manuel E. Front Microbiol Microbiology The increased resistance of microorganisms to the different antimicrobials available to today has highlighted the need to find new therapeutic agents, including natural and/or synthetic antimicrobial peptides (AMPs). This study has evaluated the antimicrobial activity of synthetic peptide 35409 (RYRRKKKMKKALQYIKLLKE) against Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 15442 and Escherichia coli ML 35 (ATCC 43827). The results have shown that peptide 35409 inhibited the growth of these three bacterial strains, having 16-fold greater activity against E. coli and P. aeruginosa, but requiring less concentration regarding E. coli (22 μM). When analyzing this activity against E. coli compared to time taken, it was found that this peptide inhibited bacterial growth during the first 60 min and reduced CFU/mL 1 log after 120 min had elapsed. This AMP permeabilized the E. coli membrane by interaction with membrane phospholipids, mainly phosphatidylethanolamine, inhibited cell division and induced filamentation, suggesting two different targets of action within a bacterial cell. Cytotoxicity studies revealed that peptide 35409 had low hemolytic activity and was not cytotoxic for two human cell lines. We would thus propose, in the light of these findings, that the peptide 35409 sequence should provide a promising template for designing broad-spectrum AMPs. Frontiers Media S.A. 2016-12-20 /pmc/articles/PMC5167725/ /pubmed/28066341 http://dx.doi.org/10.3389/fmicb.2016.02006 Text en Copyright © 2016 Barreto-Santamaría, Curtidor, Arévalo-Pinzón, Herrera, Suárez, Pérez and Patarroyo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Barreto-Santamaría, Adriana
Curtidor, Hernando
Arévalo-Pinzón, Gabriela
Herrera, Chonny
Suárez, Diana
Pérez, Walter H.
Patarroyo, Manuel E.
A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35
title A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35
title_full A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35
title_fullStr A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35
title_full_unstemmed A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35
title_short A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35
title_sort new synthetic peptide having two target of antibacterial action in e. coli ml35
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167725/
https://www.ncbi.nlm.nih.gov/pubmed/28066341
http://dx.doi.org/10.3389/fmicb.2016.02006
work_keys_str_mv AT barretosantamariaadriana anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT curtidorhernando anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT arevalopinzongabriela anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT herrerachonny anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT suarezdiana anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT perezwalterh anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT patarroyomanuele anewsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT barretosantamariaadriana newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT curtidorhernando newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT arevalopinzongabriela newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT herrerachonny newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT suarezdiana newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT perezwalterh newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35
AT patarroyomanuele newsyntheticpeptidehavingtwotargetofantibacterialactioninecoliml35